Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001–2018: a national population-based cohort study

[1]  D. Tyler,et al.  Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013 , 2022, JAMA network open.

[2]  Chih-Cheng Hsu,et al.  Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010-2018. , 2022, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  Weiming Chen,et al.  Computational Analysis of Naturally Occurring Aristolochic Acid Analogues and Their Biological Sources , 2021, Biomolecules.

[4]  E. Rammant,et al.  The incidence and prevalence of upper tract urothelial carcinoma: a systematic review , 2021, BMC Urology.

[5]  H. Weng,et al.  Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019 , 2021, Military Medical Research.

[6]  S. Freedland,et al.  Estimated Costs and Long-term Outcomes of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System , 2021, JAMA network open.

[7]  Prashanth Rawla,et al.  Epidemiology of Bladder Cancer , 2020, Medical sciences.

[8]  Wen-Chung Lee,et al.  Reduction in the Incidence of Urological Cancers after the Ban on Chinese Herbal Products Containing Aristolochic Acid: An Interrupted Time-Series Analysis , 2019, Scientific Reports.

[9]  D. Krewski,et al.  Development of a database on key characteristics of human carcinogens , 2019, Journal of toxicology and environmental health. Part B, Critical reviews.

[10]  Wen-Chung Lee,et al.  Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[11]  L. See,et al.  Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan , 2018, Pharmacoepidemiology and drug safety.

[12]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[13]  M. Wong,et al.  The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection , 2018, Scientific Reports.

[14]  H. Nishiyama,et al.  Epidemiology of urothelial carcinoma , 2017, International journal of urology : official journal of the Japanese Urological Association.

[15]  H. Chiou,et al.  Clinical and demographic characteristics among patients with urothelial carcinomas of the upper urinary tract and bladder in Taiwan , 2017, Journal of the Chinese Medical Association : JCMA.

[16]  I. Rietjens,et al.  Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach , 2016, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[17]  K. Chow,et al.  Data quality at the Singapore Cancer Registry: An overview of comparability, completeness, validity and timeliness. , 2016, Cancer epidemiology.

[18]  P. Chou,et al.  The trends of utilization in traditional Chinese medicine in Taiwan from 2000 to 2010 , 2016, Medicine.

[19]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[20]  Pau-Chung Chen,et al.  Chinese Herbs Containing Aristolochic Acid Associated with Renal Failure and Urothelial Carcinoma: A Review from Epidemiologic Observations to Causal Inference , 2014, BioMed research international.

[21]  Jing-Shiang Hwang,et al.  Increased Upper and Lower Tract Urothelial Carcinoma in Patients with End-Stage Renal Disease: A Nationwide Cohort Study in Taiwan during 1997–2008 , 2014, BioMed research international.

[22]  Lukáš Václavík,et al.  Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography–multistage fragmentation mass spectrometry , 2014, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[23]  A. Grollman,et al.  Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease , 2013, Environmental and molecular mutagenesis.

[24]  Pau-Chung Chen,et al.  Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. , 2013, The Journal of urology.

[25]  L. Tryggvadottir,et al.  Data quality at the Icelandic Cancer Registry: Comparability, validity, timeliness and completeness , 2012, Acta oncologica.

[26]  Arthur P. Grollman,et al.  Aristolochic acid-associated urothelial cancer in Taiwan , 2012, Proceedings of the National Academy of Sciences.

[27]  D. Silverman,et al.  Association between smoking and risk of bladder cancer among men and women. , 2011, JAMA.

[28]  E. Dooley.  The Beat , 2011, Environmental Health Perspectives.

[29]  Pau-Chung Chen,et al.  Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Pau-Chung Chen,et al.  Population-Based Case–Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk , 2010, Journal of the National Cancer Institute.

[31]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[32]  Jung-Der Wang,et al.  Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003 , 2008, Chinese medicine.

[33]  M. Bates,et al.  Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. , 2007, Journal of the National Cancer Institute.

[34]  J. Stein,et al.  Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. , 2007, The Journal of urology.

[35]  M. Stampfer,et al.  Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow‐up study , 2007, International journal of cancer.

[36]  R. Upton,et al.  Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[37]  Chun-Yuh Yang,et al.  Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. , 2005, Environmental research.

[38]  Graham M Lord,et al.  Urothelial malignant disease and Chinese herbal nephropathy , 2001, The Lancet.

[39]  B. Schwetz.  Safety of Aristolochic Acid , 2001 .

[40]  P. Vereerstraeten,et al.  Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) , 2000, The New England journal of medicine.

[41]  D A Kessler,et al.  Cancer and herbs. , 2000, The New England journal of medicine.

[42]  Y. Ko,et al.  Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. , 1998, Journal of toxicology and environmental health. Part A.

[43]  S. You,et al.  A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. , 1986, British Journal of Cancer.